Azido & Nitroso Impurities Characterization

Growing capabilities in complex peptides, combining advanced expertise, quality-focused processes and reliable support for pharmaceutical partners

Specialized capabilities in iron complexes, supported by strong chemistry expertise and a commitment to quality and reliable supply.

Strong organic synthesis capabilities enabling the development of diverse and complex pharmaceutical molecules with quality at every stage.

Established achiral chemistry capabilities supporting diverse pharmaceutical development and manufacturing requirements.

Ampoule-based injectable solutions supported by robust manufacturing capabilities and consistent quality.

Innovative drug delivery formats designed to support convenience, ease of use and patient-centric care.

A broad capsule portfolio combining quality, consistency and reliable pharmaceutical manufacturing.

Comprehensive carbohydrate chemistry capabilities supported by experienced teams and a strong focus on quality and scalability.

Specialized depot injection capabilities supporting long-acting therapeutic solutions.

Dedicated capabilities for genotoxic impurity characterization, supporting pharmaceutical partners in their quality and development requirements.

A range of granule-based formulations designed to support convenient and versatile drug delivery.

Specialized expertise in heterocyclic chemistry, supporting a broad range of pharmaceutical molecules and development needs.

MSN Group is one of the fastest-growing, research-based and fully integrated pharmaceutical companies based out of Hyderabad, India. It was founded in the year 2003 with a mission to make high-quality medicines affordable and accessible to the world. The organization presently has 24 state-of-the-art manufacturing facilities (16 API and 8 Finished Dosage Facilities) established across India and USA. The group has an integrated R&D centre that facilitates the research of both API and Finished Dosages under one roof, enabling the organization to introduce new and affordable therapies in global markets swiftly.